Nxera Pharma Co., Ltd.
Lilly Acquires Nexera Pharma’s Partner Centessa
Lilly acquires the OX2 agonist series from Nexera Pharma’s partner Centessa. Nexera Pharma retains milestone and royalty rights and expects mid- to long-term business profit growth.
Key Figures
- Maximum Milestone Amount: 694 million USD (approx. 110.9 billion JPY)
- Acquisition Announcement Date: 2026-03-31
- Impact on Full-Year Consolidated Results for Fiscal Year Ending December 2026: None
AI要約
Overview of the M&A
Centessa Pharmaceuticals Limited, a partner of Nexera Pharma Inc., was acquired by Eli Lilly and Company on March 31, 2026. Centessa’s OX2 agonist series (cleminorexton/ORX750, ORX142, ORX489) were co-created using Nexera Pharma’s proprietary NxStaR™ technology. Nexera Pharma continues to retain rights to receive milestones and royalties and holds a partial stake in Centessa’s shares.
Future Outlook and Impact on Corporate Value
While this acquisition has no impact on the full-year consolidated results for the fiscal year ending December 2026, it is expected to contribute to business profit and corporate value enhancement over the mid- to long-term. Nexera Pharma will leverage its NxWave™ GPCR structure-based drug discovery platform to focus on developing new pipelines for metabolic and rare endocrine diseases, thereby continuing to provide innovative pharmaceuticals that meet global unmet medical needs.
